EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Gene Targeted Therapies for Neurodegenerative Disorders: Strategies and Implications in ALS and SMA

Ayse Yesbek Kaymaz iD, Gamze Bora-Akoğlu, Hayat Erdem Yurter, Christopher Grunseich

Genes · 01.04.2026 · 17 (4) · 419

DOI: 10.3390/genes17040419 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Genes, online erschienen am 01.04.2026. Verfasst von Ayse Yesbek Kaymaz und 3 weiteren Autor:innen. Beteiligte Einrichtung: National Institute of Neurological Disorders and Stroke, National Institutes of Health, 35 Convent Dr., Bethesda, MD 20892, USA. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Genetic Therapy, Muscular Atrophy, Spinal, Neurodegenerative Diseases. Die Arbeit nennt 208 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Advances in technology have provided a better understanding of the genetic basis of neurodegenerative disorders and their underlying molecular pathophysiology. However, treating these disorders with conventional strategies is a major challenge. The approval of gene targeted therapy for spinal muscular atrophy (SMA) has laid the foundation for developing highly personalized therapies for other neurodegenerative disorders. As intensive research and efforts to advance gene targeted therapies continue, this review provides an overview of viral and non-viral vectors and delivery methods, as well as treatment strategies, including gene addition, replacement, editing, silencing, and splice modulation. Gene targeted approaches and clinical trials for SMA and amyotrophic lateral sclerosis (ALS) have demonstrated success, and additional studies are in progress. The design of efficient clinical trials which facilitate successful translation into clinical practice is of critical importance. Key considerations include the selection of appropriate disease models, understanding the natural history of the disease, and establishing well-defined outcome measures to assess prognosis of the disease and therapeutic efficacy. Finally, the precision of CRISPR-based gene editing offers the potential for one-time corrective therapies for monogenic disorders like SMA and SOD1-ALS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyotrophic Lateral SclerosisGenetic TherapyMuscular Atrophy, SpinalNeurodegenerative DiseasesGene TargetingHumansAnimalsGenetic VectorsGene EditingGene Therapy Agents

Stichwörter der Autor:innen

amyotrophic lateral sclerosisclinical trial readinessgene therapyspinal muscular atrophy

Autor:innen und Institutionen

  • National Institute of Neurological Disorders and Stroke, National Institutes of Health, 35 Convent Dr., Bethesda, MD 20892, USA.
  • Faculty of Medicine, Department of Medical Biology, Hacettepe University, 06100 Ankara, Turkey.

ORCID-Profile: Ayse Yesbek Kaymaz

Zitieren

APA

Yesbek Kaymaz, A., Bora-Akoğlu, G., Erdem Yurter, H., & Grunseich, C. (2026). Gene Targeted Therapies for Neurodegenerative Disorders: Strategies and Implications in ALS and SMA. Genes, 17(4), 419. https://doi.org/10.3390/genes17040419

Vancouver

Yesbek Kaymaz A, Bora-Akoğlu G, Erdem Yurter H, Grunseich C. Gene Targeted Therapies for Neurodegenerative Disorders: Strategies and Implications in ALS and SMA. Genes. 2026;17(4):419. doi:10.3390/genes17040419

BibTeX
@article{YesbekKaymaz2026,
  author = {Yesbek Kaymaz, Ayse and Bora-Akoğlu, Gamze and Erdem Yurter, Hayat and Grunseich, Christopher},
  title = {Gene Targeted Therapies for Neurodegenerative Disorders: Strategies and Implications in ALS and SMA},
  journal = {Genes},
  year = {2026},
  volume = {17},
  number = {4},
  pages = {419},
  doi = {10.3390/genes17040419}
}
Kostenlos starten →